Investors Buy Thermo Fisher Scientific (TMO) on Weakness
Traders purchased shares of Thermo Fisher Scientific Inc (NYSE:TMO) on weakness during trading hours on Monday. $220.17 million flowed into the stock on the tick-up and $156.80 million flowed out of the stock on the tick-down, for a money net flow of $63.37 million into the stock. Of all equities tracked, Thermo Fisher Scientific had the 20th highest net in-flow for the day. Thermo Fisher Scientific traded down ($10.17) for the day and closed at $182.03
Several equities research analysts have recently commented on TMO shares. Cowen reissued a “buy” rating and issued a $200.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 1st. Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a research note on Thursday, September 7th. Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price for the company. Finally, Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, October 26th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $205.21.
The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The stock has a market cap of $72,993.19, a PE ratio of 20.00, a PEG ratio of 1.67 and a beta of 1.06.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be given a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
In other news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares in the company, valued at approximately $47,582,981.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.49% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of TMO. BlackRock Inc. lifted its holdings in Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after acquiring an additional 22,165,530 shares in the last quarter. Capital Research Global Investors lifted its holdings in Thermo Fisher Scientific by 29.8% during the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Thermo Fisher Scientific by 2,058.1% during the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares in the last quarter. Veritas Asset Management LLP lifted its holdings in Thermo Fisher Scientific by 112.4% during the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after acquiring an additional 1,286,259 shares in the last quarter. Finally, Harbour Capital Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 18,197.5% in the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock valued at $6,884,000 after purchasing an additional 1,194,487 shares in the last quarter. Hedge funds and other institutional investors own 86.16% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/06/investors-buy-thermo-fisher-scientific-tmo-on-weakness.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.